Rubicon Research Peer Comparison
NSE: RUBICON | BSE: 544578
₹1,610.50
₹51.20
(3.28%)
As on 30-Oct-2026IST
Market cap
₹26,650 Cr
Revenue (TTM)
₹1,936 Cr
P/E Ratio
92.5
P/B Ratio
19.9
Div. Yield
0.1 %
Edit
| Rubicon Research | Acutaas Chemicals | Piramal Pharma | Wockhardt | Granules India | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
26,650 | 32,770 | 31,826 | 30,814 | 22,901 |
Revenue (₹ Cr) |
1,936 | 1,593 | 9,779 | 3,564 | 5,632 |
Net Profit (₹ Cr) |
288.22 | 438.64 | -270.51 | 414.00 | 662.35 |
Net Margin (%) |
14.79 | 27.16 | -2.71 | 11.23 | 11.75 |
RoE (%) |
29.77 | 25.02 | -2.55 | 8.38 | 14.34 |
Price to Earnings |
92.47 | 74.62 | -- | 75.34 | 34.58 |
Price-To-Book |
19.85 | 17.64 | 3.91 | 6.12 | 4.67 |
Income Statement (₹ Cr)
| Rubicon Research | Acutaas Chemicals | Piramal Pharma | Wockhardt | Granules India | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,935.80 | 1,592.52 | 9,778.62 | 3,564.00 | 5,632.31 |
|
Total Income
|
1,948.58 | 1,615.23 | 9,993.26 | 3,686.00 | 5,638.56 |
|
Total Expenditure
|
1,485.56 | 969.32 | 8,578.44 | 2,792.00 | 4,354.97 |
|
EBITDA
|
450.24 | 623.20 | 1,200.18 | 772.00 | 1,277.34 |
|
Depreciation
|
50.83 | 41.96 | 887.82 | 226.00 | 306.94 |
|
EBIT
|
399.41 | 581.24 | 312.36 | 546.00 | 970.39 |
|
Interest
|
40.84 | 4.21 | 347.94 | 217.00 | 111.70 |
|
Other Income
|
12.78 | 22.71 | 214.64 | 122.00 | 6.25 |
|
Exceptional Items
|
0.00 | 0.00 | -216.88 | 12.00 | 15.92 |
|
Profit before Tax
|
371.35 | 599.74 | -37.82 | 463.00 | 880.86 |
|
Provision for Tax
|
83.14 | 161.10 | 232.69 | 49.00 | 218.51 |
|
Profit after Tax
|
288.22 | 438.64 | -270.51 | 414.00 | 662.35 |
Liabilities (₹ Cr)
| Rubicon Research | Acutaas Chemicals | Piramal Pharma | Wockhardt | Granules India | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,288.82 | 1,857.45 | 8,142.24 | 4,940.00 | 5,085.00 |
|
Minority Interest
|
0.00 | 0.51 | 0.55 | -5.00 | 0.00 |
|
Non-Current Liabilities
|
202.03 | 47.15 | 5,213.99 | 1,712.00 | 542.92 |
|
Current Liabilities
|
835.87 | 253.37 | 5,158.51 | 1,622.00 | 2,092.03 |
|
Total Liabilities
|
2,326.71 | 1,983.96 | 17,723.32 | 8,578.00 | 7,682.91 |
Assets (₹ Cr)
| Rubicon Research | Acutaas Chemicals | Piramal Pharma | Wockhardt | Granules India | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
519.60 | 1,132.12 | 10,687.30 | 5,343.00 | 3,533.26 |
|
Current Assets
|
1,681.81 | 1,012.00 | 7,253.65 | 2,606.00 | 3,767.65 |
|
Total Assets
|
2,326.71 | 1,983.96 | 17,723.32 | 8,578.00 | 7,682.91 |
|
Total Debt*
|
259.37 | 26.49 | 5,495.48 | 2,125.00 | 1,338.13 |
|
Net Current Assets
|
845.94 | 758.64 | 2,095.14 | 984.00 | 1,675.62 |
|
Contingent Liabilities
|
19.09 | 17.25 | 95.72 | 768.26 | 0.93 |
Cashflow (₹ Cr)
| Rubicon Research | Acutaas Chemicals | Piramal Pharma | Wockhardt | Granules India | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
205.05 | 292.17 | 1,652.60 | 390.00 | 793.25 |
|
Cash Flow from Investing Activities
|
-409.72 | -265.94 | -826.03 | -241.00 | -773.21 |
|
Cash from Financing Activities
|
283.07 | 4.10 | -38.98 | -54.00 | 379.29 |
|
Net Cash Inflow / Outflow
|
78.39 | 30.33 | 787.59 | 95.00 | 399.33 |
Ratios
Profitability Ratios
| Rubicon Research | Acutaas Chemicals | Piramal Pharma | Wockhardt | Granules India | |
|---|---|---|---|---|---|
|
ROCE (%)
|
29.22 | 32.42 | 1.24 | 6.79 | 15.74 |
|
ROE (%)
|
29.77 | 25.02 | -2.55 | 8.38 | 14.34 |
|
ROA (%)
|
24.77 | 22.40 | -1.56 | 4.94 | 9.48 |
|
EBIT Margin (%)
|
20.63 | 36.50 | 3.19 | 15.32 | 17.23 |
|
Net Margin (%)
|
14.79 | 27.16 | -2.71 | 11.23 | 11.75 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Rubicon Research | Acutaas Chemicals | Piramal Pharma | Wockhardt | Granules India | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
46.65 | 45.18 | 9.43 | 18.37 | 24.83 |
|
EBIT Growth (%)
|
62.13 | 115.51 | -3.72 | 252.26 | 40.39 |
|
Net Profit Growth (%)
|
89.49 | 95.80 | -199.34 | 377.85 | 38.13 |
|
EPS Growth (%)
|
78.60 | 63.29 | -410.28 | 1,001.33 | 34.88 |
|
Book Value Growth (%)
|
144.31 | 26.03 | 0.33 | 13.47 | 27.49 |
Valuation Ratios
| Rubicon Research | Acutaas Chemicals | Piramal Pharma | Wockhardt | Granules India | |
|---|---|---|---|---|---|
|
Price / Earnings
|
91.04 | 74.62 | -153.04 | 77.32 | 31.71 |
|
Price / Book Value
|
19.85 | 17.64 | 3.91 | 6.12 | 4.67 |
|
Dividend Yield (%)
|
0.09 | 0.06 | 0.00 | 0.00 | 0.21 |
|
EV/EBITDA
|
59.00 | 52.27 | 29.97 | 41.81 | 18.23 |
|
Market Cap (₹ Cr)
|
12,753.19 | 20,944.75 | 18,108.89 | 19,071.62 | 15,391.88 |
Solvency Ratios
| Rubicon Research | Acutaas Chemicals | Piramal Pharma | Wockhardt | Granules India | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.11 | 0.02 | 0.55 | 0.31 | 0.06 |
|
Short term debt to equity ratio
|
0.05 | 0.00 | 0.09 | 0.09 | 0.20 |
|
Current Ratio
|
2.01 | 3.99 | 1.41 | 1.61 | 1.80 |
|
Quick Ratio
|
1.14 | 2.89 | 0.77 | 1.06 | 1.00 |
|
Interest Coverage
|
10.09 | 143.52 | 0.89 | 3.13 | 8.89 |
Operating Efficiency Ratios
| Rubicon Research | Acutaas Chemicals | Piramal Pharma | Wockhardt | Granules India | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
26.28 | 22.50 | 23.05 | 16.50 | 16.15 |
|
Asset Turnover
|
1.66 | 0.81 | 0.56 | 0.43 | 0.81 |
|
Receivable days
|
40.13 | 88.98 | 78.20 | 58.75 | 33.72 |
|
Inventory Days
|
60.29 | 56.04 | 93.30 | 75.82 | 54.92 |
|
Payable days
|
232.47 | 99.95 | 226.14 | 186.21 | 136.11 |
|
Cash Conversion Cycle
|
-132.04 | 45.07 | -54.64 | -51.64 | -47.47 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
